Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9269272 | 0.87 | TSHR (0.48) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL5426303 | 0.84 | MAPT (0.53) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL11052562 | 0.83 | MAPT (0.61) | MAPTALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL128166 | 0.83 | TSHR (0.45) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL5323320 | 0.81 | MAPT (0.50) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL5329373 | 0.81 | MAPT (0.50) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL5465254 | 0.81 | MAPK1 (0.45) | SMN1; SMN2MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL5471001 | 0.80 | AR (0.44) | SMN1; SMN2ALDH1A1LMNAHTTTSHR | |
| SCHEMBL5453599 | 0.80 | MAPT (0.64) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL11045778 | 0.79 | GLA (0.42) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | SMN1; SMN2 4424/4885NPC1 1089/4885RAB9A 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.